| Stage | Findings |
| No DR | No abnormalities |
| Mild NPDR | Microaneurysms only |
| Moderate NPDR | Microaneurysms + dot/blot hemorrhages, hard exudates, cotton-wool spots, venous beading |
| Severe NPDR | 4-2-1 rule: hemorrhages in 4 quadrants, venous beading in 2+, IRMA in 1+ |
| PDR | Neovascularization (NVD, NVE), vitreous/preretinal hemorrhage, traction retinal detachment |
| DME (any stage) | Retinal thickening within 1 disc diameter of fovea (clinically significant macular edema) |
Treatment
- Anti-VEGF (intravitreal): Aflibercept, ranibizumab, faricimab, bevacizumab – first-line for DME and PDR.
- Panretinal photocoagulation (PRP): For high-risk PDR; reduces severe vision loss by 50%.
- Focal/grid laser: For non-center-involving DME (less used now).
- Vitrectomy: Non-clearing vitreous hemorrhage, traction detachment.
- Corticosteroids (intravitreal/implants): Refractory DME; cataract/IOP risks.
Systemic Control
Intensive glycemic control (HbA1c <7%), blood pressure control (<130/80), lipid management (statin), and smoking cessation slow DR progression.
Diabetes - Related Articles